American Joint Committee on Cancer Staging and Other Platforms to Assess Prognosis and Risk
- PMID: 34503720
- DOI: 10.1016/j.cps.2021.05.004
American Joint Committee on Cancer Staging and Other Platforms to Assess Prognosis and Risk
Abstract
The eighth edition of the American Joint Committee on Cancer melanoma staging system relies on assessments of the primary tumor (T), regional lymph nodes (N), and distant metastatic sites (M). Its notable updates include tumor thickness measurements to the nearest 0.1 mm, revision of T1a and T1b definitions, re-evaluation of N category descriptors, increased number of stage III subgroupings, and incorporation of a new M1d designation, among others. These changes were based on analyses of a large contemporary international melanoma database. Ultimately, these revisions were made to improve staging and prognostication, risk stratification, and selection of patients for clinical trials.
Keywords: Melanoma; Prognosis; Sentinel lymph node biopsy; Staging; Survival.
Copyright © 2021 Elsevier Inc. All rights reserved.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
